PIK3CA P447_L455del

CI-VAR-00003347Explore in graph →CIViC 3458

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Estrogen Receptor-positive Breast Cancer1unmapped disease
PIK3CA P447_L455del	Alpelisib + LetrozoleCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID9575 A phase Ib trial assessed preliminary activity of the PIK3CA inhibitor alpelisib in combination with letrozole in ER+/PIK3CA mutant patients. One patient was found to harbor a novel deletion in the C2… (full text at CIViC) PMID 27126994 · Mayer et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.